U.S. pays three times more for drugs
The finding underscores a transatlantic gulf between the price of treatments for a range of diseases and follows demands for lower drug costs.
The 20 medicines, which together accounted for 15 percent of global pharmaceuticals spending in 2014, are a major source of profits for companies including AbbVie, AstraZeneca, Merck, Pfizer and Roche.
Researchers from Britain's University of Liverpool also found U.S. prices were consistently higher than in other European markets.
Elsewhere, U.S. prices were six times higher than in Brazil and 16 times higher than the average in the lowest-price country, which was usually India.
You can read the whole story here. ■